Trials / Completed
CompletedNCT00529451
Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg
An Eight Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing the Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg to Ramipril 5 mg in Patients With Essential Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,613 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to investigate the efficacy, safety and tolerability of aliskiren 300 mg, 150 mg and 75 mg when compared to ramipril 5 mg in patients with essential hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aliskiren | Aliskiren |
| DRUG | Ramipril | comparator |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2007-09-14
- Last updated
- 2011-03-25
- Results posted
- 2011-03-25
Locations
3 sites across 3 countries: China, India, Thailand
Source: ClinicalTrials.gov record NCT00529451. Inclusion in this directory is not an endorsement.